Scimcon, the decades-strong leader in scientific informatics for the lab, has announced in 2021 that it has made a company-wide commitment to support Blood Cancer UK. After years of ad hoc charitable donations, Scimcon has decided that from 2021 the company will support one charity, and going forward all its charitable donations will be related to fundraising in the cause of Blood Cancer UK.
Geoff Parker, our co-founder explains: “When we really thought about it, it makes sense to ensure that the entire company aligns behind one cause. A company’s charitable contributions are not insignificant over time, and that’s why we are determined that every dollar and penny of our charitable contributions going forward will all be donated to our charity of choice. This means that every member of staff in Scimcon understands that from this year, without fail, we will all support this charity.”
Blood Cancer UK is a community dedicated to beating blood cancer. They do this by funding research and supporting those affected. Since 1960, the charity has invested over £500 million in blood cancer research, transforming treatments and saving lives. Right now, the Blood Cancer UK community is funding 167 researchers and staff across the UK who are searching for the next breakthrough. The day we will beat blood cancer is now in sight, and the charity’s researchers are determined to finish the job.
The charity also campaigns for change, helping to make sure that people get the healthcare they deserve, and that new treatments that come from research breakthroughs are available on the NHS.
Geoff adds, “As scientists working with scientific companies, Scimcon is committed to investment in science – it is our lifeblood. The fact that Blood Cancer UK is funding lifesaving research appeals to our ethos as a business. You only have to read the most recent annual report from the charity to learn what their money is spent on: Survival rates have improved dramatically over the last few decades, and even over the last 10 years we have seen blood cancer survival rates increase faster than survival rates for other cancers.”
In 2020, investing in life-saving research remained at the heart of their work, with the announcement of £6.5 million of new research funding. This money was spread across 15 projects, supporting the work of 169 researchers at 30 research institutions. This included a series of projects focused on acute myeloid leukaemia, which has one of the poorest outcomes. The researchers will identify better treatment targets, test the potential for repurposing existing drugs, and develop new ways to predict which patients will respond to current treatments.
They are also funding research that will look at how a key gene drives cancer development in children with Down’s Syndrome. Two Lymphoma teams will look at the role of the Epstein Barr Virus in the development of lymphomas, focusing on lymphomas and other blood cancers that develop as a result of treatment in people who have had an organ transplant. Blood Cancer UK also funded new research in myeloma, that will look at how myeloma develops and how patients respond to immunotherapies.
Thanks to previously funded research, there were 117 papers published in scientific journals during 2019/20. These papers covered a wide range of science, from laboratory research to clinical trials, and covered the full range of blood cancers. Geoff explains “In our small way, Scimcon might be working with companies who contribute to this mammoth effort. Our customers in laboratories worldwide are part of this great community, and Scimcon believes that money is only part of the effort to save lives. We are proud to be associated with Blood Cancer UK as our charity of choice.”
To learn more about the life-saving work Blood Cancer UK does, visit www.bloodcancer.org.uk